AR105413A1 - Composición farmacéutica para el tratamiento de enfermedades gastrointestinales - Google Patents

Composición farmacéutica para el tratamiento de enfermedades gastrointestinales

Info

Publication number
AR105413A1
AR105413A1 ARP160100272A ARP160100272A AR105413A1 AR 105413 A1 AR105413 A1 AR 105413A1 AR P160100272 A ARP160100272 A AR P160100272A AR P160100272 A ARP160100272 A AR P160100272A AR 105413 A1 AR105413 A1 AR 105413A1
Authority
AR
Argentina
Prior art keywords
treatment
pharmaceutical composition
gastrointestinal diseases
sucralfate
particle size
Prior art date
Application number
ARP160100272A
Other languages
English (en)
Original Assignee
Dae Woong Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55169799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR105413(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dae Woong Pharma filed Critical Dae Woong Pharma
Publication of AR105413A1 publication Critical patent/AR105413A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica para el tratamiento de enfermedades gastrointestinales caracterizado porque comprende ranitidina, sucralfato y subcitrato de bismuto como componentes activos y que satisface por lo menos una de las siguientes condiciones: (a) el sucralfato tiene un tamaño de partícula promedio de 1 a 25 mm, (b) el subcitrato de bismuto tiene un tamaño de partícula promedio de 5 a 90 mm.
ARP160100272A 2015-01-30 2016-01-29 Composición farmacéutica para el tratamiento de enfermedades gastrointestinales AR105413A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20150015339 2015-01-30

Publications (1)

Publication Number Publication Date
AR105413A1 true AR105413A1 (es) 2017-10-04

Family

ID=55169799

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160100272A AR105413A1 (es) 2015-01-30 2016-01-29 Composición farmacéutica para el tratamiento de enfermedades gastrointestinales

Country Status (19)

Country Link
EP (1) EP3250199A4 (es)
JP (1) JP6419347B2 (es)
KR (2) KR101583452B1 (es)
CN (1) CN107205947B (es)
AR (1) AR105413A1 (es)
CL (1) CL2017001680A1 (es)
CO (1) CO2017006222A2 (es)
EA (1) EA032385B9 (es)
EC (1) ECSP17038599A (es)
GE (1) GEP20196941B (es)
MA (1) MA41432A (es)
MX (1) MX2017007567A (es)
MY (1) MY195824A (es)
PE (1) PE20171340A1 (es)
PH (1) PH12017550051A1 (es)
SA (1) SA517382016B1 (es)
TW (1) TWI635859B (es)
UA (1) UA116517C2 (es)
WO (1) WO2016122226A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101988479B1 (ko) 2017-10-11 2019-09-24 (주)휴럼 리트세노라이드를 유효성분으로 하는 헬리코박터 파이로리 균주로부터 유래되는 위장질환 예방 및 치료용 약학 조성물
JP2021518422A (ja) * 2018-04-13 2021-08-02 サムヤン バイオファーマシューティカルズ コーポレイションＳａｍｙａｎｇ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐｏｒａｔｉｏｎ レナリドミドを含む医薬組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3874917T2 (de) * 1987-03-09 1993-03-04 Procter & Gamble Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen.
US4990610A (en) * 1988-08-25 1991-02-05 Applied Analytical Industries, Inc. Method for preparing high potency sucralfate
EP0403048A3 (en) * 1989-06-14 1991-01-30 Warner-Lambert Company Medicated compositions containing sucralfate and processes for their production
KR970006083B1 (ko) * 1992-01-22 1997-04-23 주식회사 대웅제약 위장질환 치료용 의약 조성물
BR9507533A (pt) * 1994-04-26 1997-09-02 Chugai Pharmaceutical Co Ltd Preparações de sucralfato granulado fundido e um processo para sua produção
JPH0879097A (ja) * 1994-09-01 1996-03-22 Matsushita Electric Ind Co Ltd 携帯無線機
KR970006083A (ko) 1995-07-06 1997-02-19 한승준 자동차용 카울부의 와이어 고정장치 취부구조
WO1999010000A1 (en) * 1997-08-25 1999-03-04 The Procter & Gamble Company Combined preparations for treating upper gastrointestinal tract distress
WO2000078307A1 (en) * 1999-06-21 2000-12-28 Daewoong Pharmaceutical Co., Ltd. Orally administrable pharmaceutical preparation having therapeutic effect on gastrointestinal disorders comprising coated ranitidine, bismuth subcitrate and sucralfate
JP2006076956A (ja) * 2004-09-10 2006-03-23 Taiyo Yakuhin Kogyo Kk 胃炎の治療・予防用配合剤
KR101617054B1 (ko) * 2008-07-01 2016-04-29 라이온 가부시키가이샤 고형내복제제
KR20110105223A (ko) * 2010-03-18 2011-09-26 일양약품주식회사 일라프라졸 및 수크랄페이트와 비스무스 제제의 혼합물을 함유하는 위장질환을 예방 또는 치료하기 위한 경구용 약제 조성물
KR20140072673A (ko) * 2012-12-05 2014-06-13 (주)한국파비스제약 경구용 위장질환 치료를 위한 정제

Also Published As

Publication number Publication date
KR20160094268A (ko) 2016-08-09
JP6419347B2 (ja) 2018-11-07
CN107205947A (zh) 2017-09-26
TW201639559A (zh) 2016-11-16
BR112017013857A2 (pt) 2018-02-27
EA201791458A1 (ru) 2017-11-30
UA116517C2 (uk) 2018-03-26
CL2017001680A1 (es) 2018-01-12
EA032385B1 (ru) 2019-05-31
KR101583452B9 (ko) 2022-05-02
GEP20196941B (en) 2019-01-10
ECSP17038599A (es) 2017-09-29
EP3250199A2 (en) 2017-12-06
MA41432A (fr) 2017-12-05
CO2017006222A2 (es) 2017-09-20
PE20171340A1 (es) 2017-09-13
CN107205947B (zh) 2020-05-22
KR101583452B1 (ko) 2016-01-11
WO2016122226A3 (en) 2016-09-15
MX2017007567A (es) 2017-10-19
PH12017550051A1 (en) 2018-01-29
JP2018503672A (ja) 2018-02-08
TWI635859B (zh) 2018-09-21
EP3250199A4 (en) 2018-08-08
WO2016122226A2 (en) 2016-08-04
MY195824A (en) 2023-02-22
EA032385B9 (ru) 2019-07-31
SA517382016B1 (ar) 2021-03-18

Similar Documents

Publication Publication Date Title
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
MX2022015755A (es) Profarmacos de hormona paratiroidea (pth).
BR112017023853A2 (pt) composições de nanopartícula para terapia sustentada.
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
CL2016002971A1 (es) Combinación.
NI201600071A (es) Compuestos de inhibidor de autotaxina
CL2018000565A1 (es) Compuestos derivados de piridinona dicarboxamida, inhibidores de bromodominio; composicion farmaceutica; combinacion farmaceutica; utiles en el tratamiento de enfermedades autoinmunitarias, inflamatorias, virales y cancer, entre otras.
CL2015002546A1 (es) Derivados 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftálmicos
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
BR112018005754A2 (pt) benzamidas substituídas por isoxazolina e análogos como inseticidas.
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
CO2017002472A2 (es) Formulación de acetato de abiraterona
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
ECSP17044282A (es) Formulación de relación fija de insulina glargina/lixisenatida
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
WO2014153009A3 (en) Thiosaccharide mucolytic agents
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
BR112015016033A2 (pt) composições e métodos para tratamento de infecções por bactérias
CO2018008626A2 (es) Formulaciones de oritavancina
AR105413A1 (es) Composición farmacéutica para el tratamiento de enfermedades gastrointestinales
BR112017001888A2 (pt) formulações biológicas para instilação intravesical
MX2017013879A (es) Composiciones que comprenden anakinra.